Ralph Zinner

Ralph Zinner

UNVERIFIED PROFILE

Are you Ralph Zinner?   Register this Author

Register author
Ralph Zinner

Ralph Zinner

Publications by authors named "Ralph Zinner"

Are you Ralph Zinner?   Register this Author

88Publications

2359Reads

13Profile Views

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.

Bioinformatics 2019 Oct;35(19):3709-3717

Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine of Cornell University, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btz109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761967PMC
October 2019

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

JCO Clin Cancer Inform 2018 12;2:1-14

Goldy C. George, Adrianna Buford, Kenneth Hess, Sarina A. Piha-Paul, Ralph Zinner, Vivek Subbiah, Christina Hinojosa, Charles S. Cleeland, Funda Meric-Bernstam, and David S. Hong, The University of Texas MD Anderson Cancer Center; and Elmer V. Bernstam, The University of Texas School of Biomedical Informatics, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874009PMC
December 2018

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Clin Lung Cancer 2018 11 26;19(6):e823-e830. Epub 2018 May 26.

Oncology at Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.05.013DOI Listing
November 2018

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Br J Cancer 2018 01 9;118(2):e2. Epub 2018 Jan 9.

Gastrointestinal Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Room 4M10, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785753PMC
January 2018

Lung Cancer in the Older Patient.

Clin Geriatr Med 2017 11 19;33(4):563-577. Epub 2017 Aug 19.

Division of Pulmonary and Critical Care Medicine, Sidney Kimmel Medical College of Thomas Jefferson University, 834 Walnut Street, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cger.2017.06.008DOI Listing
November 2017

Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.

J R Stat Soc Ser C Appl Stat 2017 01 11;66(1):201-224. Epub 2016 Jun 11.

Department of Investigational Cancer Therapeutics, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/rssc.12162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328131PMC
January 2017

Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases.

J Thorac Dis 2016 Sep;8(9):E1028-E1031

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.09.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059245PMC
September 2016

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 05 16;77(5):1097-102. Epub 2016 Apr 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3000-3DOI Listing
May 2016

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).

Int J Oncol 2016 Jan 29;48(1):13-27. Epub 2015 Oct 29.

Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734604PMC
January 2016

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Clin Genitourin Cancer 2015 Feb 3;13(1):e19-26. Epub 2014 Jul 3.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144738PMC
February 2015

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Invest New Drugs 2015 Feb 18;33(1):177-86. Epub 2014 Oct 18.

Sarah Cannon Research Institute at HealthONE, Presbyterian/St. Luke's Medical Center, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0173-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297242PMC
February 2015

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

J Thorac Oncol 2015 Jan;10(1):134-42

*Department of Investigational Cancer therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas; †Global Diversity/Med Affairs, Eli Lilly and Company, Indianapolis, Indiana; ‡Medical Oncology, Tennessee Oncology, Nashville, Tennessee; §Hematology/Oncology, Florida Cancer Specialists, Fort Myers, Florida; •Medical Oncology, Highlands Oncology Group, Fayetteville, Arkansas; ¶Hematology-Medical Oncology, Oncology Heamatology Care Inc., Blue Ash, Ohio; #Hematology & Oncology, Internal Medicine, ACRC/Arizona Clinical Research Center, Arizona Oncology, Tucson, Arizona; **Hematology and Oncology, Michigan State University, East Lansing, Michigan; ††Northeast Georgia Cancer Care, University of Georgia Health Sciences University, Athens, Georgia; ‡‡Statistics Oncology, §§CDK4/6 Product Team, GPORWE-Oncology, ¶¶Oncology-Global Strategic Plan, ##Oncology-Early Phase, ***US Med Affairs and Late Phase Prod Dev, †††Global Medical Communications-Oncology, and ‡‡‡Global Med Affairs & Late Phase Prod Dev, Eli Lilly and Company, Indianapolis, Indiana; §§§Department of Medicine, Oncology Division, Washington University Medical School, St. Louis, Missouri; and ••Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572PMC
January 2015

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.

Invest New Drugs 2014 Jun 5;32(3):465-72. Epub 2013 Dec 5.

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0051-8
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0051-8DOI Listing
June 2014

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.

Anticancer Res 2014 May;34(5):2349-55

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A.

View Article

Download full-text PDF

Source
May 2014

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.

Invest New Drugs 2014 Feb 23;32(1):154-9. Epub 2013 Apr 23.

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9964-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913855PMC
February 2014

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.

Invest New Drugs 2013 Dec 28;31(6):1505-13. Epub 2013 Aug 28.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0013-1DOI Listing
December 2013

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Mol Cancer Ther 2013 Oct 20;12(10):2167-75. Epub 2013 Aug 20.

Corresponding Author: Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138057PMC
October 2013

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

Oncologist 2011 21;16(3):327-35. Epub 2011 Feb 21.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-0308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228100PMC
August 2011

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).

Invest New Drugs 2011 Jun 22;29(3):499-505. Epub 2010 Jan 22.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9380-zDOI Listing
June 2011

Gene-based therapy: novel approaches.

Authors:
Ralph Zinner

J Thorac Oncol 2009 Nov;4(11 Suppl 3):S1086-9

University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JTO.0000361761.19199.6eDOI Listing
November 2009

Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.

Mol Cancer Ther 2009 Mar 10;8(3):521-32. Epub 2009 Mar 10.

Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0937DOI Listing
March 2009

Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.

Int J Radiat Oncol Biol Phys 2009 Jan 14;73(1):119-27. Epub 2008 Jun 14.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.03.069DOI Listing
January 2009

Images in clinical medicine. Reversal of laryngeal paresis.

N Engl J Med 2007 Dec;357(23):e25

University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/abs/10.1056/NEJMicm062394
Publisher Site
http://dx.doi.org/10.1056/NEJMicm062394DOI Listing
December 2007

Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.

J Thorac Oncol 2007 Aug;2(8):745-50

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641531305
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e31811f4719DOI Listing
August 2007

Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy.

J Thorac Oncol 2007 Feb;2(2):141-6

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/jto.0b013e3180311792DOI Listing
February 2007

Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.

J Thorac Oncol 2006 Jun;1(5):425-9

Department of Diagnostic Imaging, M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
June 2006

Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.

Clin Cancer Res 2005 Jun;11(11):4151-9

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1659DOI Listing
June 2005

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.

Cancer Chemother Pharmacol 2004 Oct 4;54(4):308-14. Epub 2004 Jun 4.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0816-zDOI Listing
October 2004

Pemetrexed in advanced NSCLC: a review of the clinical data.

Oncology (Williston Park) 2004 Jul;18(8 Suppl 5):54-62

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
July 2004

Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.

Clin Lung Cancer 2004 Apr;5 Suppl 2:S67-74

Department of Thoracic/Head & Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clc.2004.s.006DOI Listing
April 2004

Prostate-specific antitumor activity by probasin promoter-directed p202 expression.

Mol Carcinog 2003 Jul;37(3):130-7

Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.10129DOI Listing
July 2003

New targets for the treatment of advanced non-small cell lung cancer.

Cancer Chemother Biol Response Modif 2002 ;20:717-61

Department of Thoracic/Head and Neck Medical Oncology, University of Texas, M.D. Anderson Cancer Center, P.O. Box 432, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
May 2003

Fingerprinting the circulating repertoire of antibodies from cancer patients.

Nat Biotechnol 2003 Jan 23;21(1):57-63. Epub 2002 Dec 23.

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nbt774
Publisher Site
http://dx.doi.org/10.1038/nbt774DOI Listing
January 2003

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

Lung Cancer 2002 Jul;37(1):17-27

Department of Thoracic/Head and Neck Medical Oncology, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 M.D. Anderson Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(02)00035-1DOI Listing
July 2002